



**Cochrane**  
**Library**

Cochrane Database of Systematic Reviews

## Pharmacological interventions for people with borderline personality disorder (Protocol)

Stoffers-Winterling JM, Storebø OJ, Völlm BA, Mattivi JT, Nielsen SS, Kielsholm ML, Faltinsen EG, Simonsen E, Lieb K

Stoffers-Winterling JM, Storebø OJ, Völlm BA, Mattivi JT, Nielsen SS, Kielsholm ML, Faltinsen EG, Simonsen E, Lieb K.

Pharmacological interventions for people with borderline personality disorder.

*Cochrane Database of Systematic Reviews* 2018, Issue 2. Art. No.: CD012956.

DOI: 10.1002/14651858.CD012956.

[www.cochranelibrary.com](http://www.cochranelibrary.com)

## TABLE OF CONTENTS

HEADER . . . . .	1
ABSTRACT . . . . .	1
BACKGROUND . . . . .	1
OBJECTIVES . . . . .	4
METHODS . . . . .	4
ACKNOWLEDGEMENTS . . . . .	9
REFERENCES . . . . .	9
APPENDICES . . . . .	17
CONTRIBUTIONS OF AUTHORS . . . . .	21
DECLARATIONS OF INTEREST . . . . .	21
SOURCES OF SUPPORT . . . . .	21
NOTES . . . . .	22

[Intervention Protocol]

# Pharmacological interventions for people with borderline personality disorder

Jutta M Stoffers-Winterling<sup>1</sup>, Ole Jakob Storebø<sup>2,3a</sup>, Birgit A Völlm<sup>4</sup>, Jessica T Mattivi<sup>1</sup>, Signe Sofie Nielsen<sup>3</sup>, Maja Lærke Kielsholm<sup>3</sup>, Erlend G Faltinsen<sup>3</sup>, Erik Simonsen<sup>3b</sup>, Klaus Lieb<sup>1</sup>

<sup>1</sup>Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Mainz, Germany. <sup>2</sup>Child and Adolescent Psychiatric Department, Region Zealand, Roskilde, Denmark. <sup>3</sup>Psychiatric Research Unit, Region Zealand Psychiatry, Slagelse, Denmark. <sup>4</sup>Division of Psychiatry & Applied Psychology, University of Nottingham Innovation Park, Nottingham, UK

<sup>a</sup>Shares first authorship. <sup>b</sup>Shares last authorship.

Contact address: Ole Jakob Storebø, Child and Adolescent Psychiatric Department, Region Zealand, Birkevaenget 3, Roskilde, 4300, Denmark. [ojst@regionsjaelland.dk](mailto:ojst@regionsjaelland.dk).

**Editorial group:** Cochrane Developmental, Psychosocial and Learning Problems Group.

**Publication status and date:** New, published in Issue 2, 2018.

**Citation:** Stoffers-Winterling JM, Storebø OJ, Völlm BA, Mattivi JT, Nielsen SS, Kielsholm ML, Faltinsen EG, Simonsen E, Lieb K. Pharmacological interventions for people with borderline personality disorder. *Cochrane Database of Systematic Reviews* 2018, Issue 2. Art. No.: CD012956. DOI: 10.1002/14651858.CD012956.

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## ABSTRACT

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:

To assess the beneficial and harmful effects of pharmacological treatment for adolescents and adults with borderline personality disorder (BPD).

## BACKGROUND

### Description of the condition

Borderline personality disorder (BPD) is a condition first recognised in the 1960s (Gunderson 2009; Kernberg 1967; Kernberg 1975). Historically, the term BPD was coined by Adolph Stern to describe a condition in the 'borderland' between psychosis and neurosis (Stern 1938). Subsequent psychoanalytic contributions (especially that of Kernberg 1975) have reaffirmed this distinction, emphasising that the capacity to test reality remains grossly intact but is subject to subtle distortions, especially under stress.

According to current diagnostic criteria, BPD is characterised by a pervasive pattern of instability in affect regulation, impulse control, interpersonal relationships, and self-image (APA 2013; WHO 1993). Clinical hallmarks include emotional dysregulation, impulsive aggression, repeated self-injury, and chronic suicidal tendencies (Fonagy 2009; Lieb 2004). Whereas some authors have suggested that it is a variant of affective disorders (Akiskal 2004), others claim that it is only the causes of these diseases that partially overlap (Paris 2007). Despite the classification challenges in defining and delimiting the condition, BPD is still being widely researched. Its importance stems from the large amount of suffering of the persons concerned (Stiglmayr 2005; Zanarini 1998), debilitating functional impairments (Gunderson 2011a; Gunderson 2011b; Niesten 2016; Skodol 2002; Soetmann 2008b), and from

the significant impact it has on mental health services (Cailhol 2015; Hörz 2010; Soetmann 2008a; Tyrer 2015; Zanarini 2004a; Zanarini 2012). It is estimated that about 60% to 78% of BPD patients attempt suicide (Links 2009), though the rate of completed suicides is far less. Zanarini and colleagues found suicide rates of 4.5% during 16 years of follow-up (Zanarini 2015), whereas Stone 1993 reported a suicide rate of 8.5% after 16.5 years. Study estimates of the lifetime risk of suicide among patients with BPD range from 3% to 10% (Links 2009). Suicidal behaviour is reported to occur in up to 84% of patients with BPD (Goodman 2012; Soloff 2002), and comorbid mood disorders or substance use disorders are the most common risk factors associated with successful suicide attempts (Black 2004; Doyle 2016; Yen 2004). The definition of BPD in the *Diagnostic and Statistical Manual of Mental Disorders* (DSM) Fifth Edition (DSM-5; APA 2013), Fourth Edition Text Revision (DSM-IV-TR; APA 2000) and Fourth Edition (DSM-IV; APA 1994) comprises nine criteria that cover the features mentioned above. At least five criteria should be met for a definite categorical BPD diagnosis to be made, and four criteria for probable diagnosis (see Appendix 1). In the alternative diagnostic classification system of the World Health Organization (WHO), the *International Classification of Diseases*, which is currently in its tenth edition (ICD-10; WHO 1993), the relating condition is referred to as “Emotionally unstable personality disorder (F60.3)”, of which there is an impulsive type (F60.30) and a borderline type (F60.31; see Appendix 2). The latter essentially overlaps with the DSM-IV definition. There are 10 possible criteria defined that very closely reflect the DSM criteria, with the exception of one criterion which is not included in the DSM (“4. Difficulty in maintaining any course of action that offers no immediate reward”; WHO 1993). Out of 10 possible criteria at least five must be met, one of which must be “a marked tendency to quarrelsome behaviour and to conflicts with others, especially when impulsive acts are thwarted or criticised”.

Overall, the prevalence of BPD in the general population is estimated to be about 1.5% (Torgersen 2012), with findings of single epidemiologic studies ranging between 0.6% (Coid 2006) and 2.7% (Trull 2010). In clinical populations BPD occurs frequently (Munk-Jørgensen 2010), with studies reporting a prevalence ranging from 9.3% to 46.3% and a mean point prevalence across studies of 28.5% (Torgersen 2012). Though BPD is predominantly diagnosed in women (75%; APA 2000), it is estimated to be equally frequent in men (Lenzenweger 2007; Ten Have 2016; Torgersen 2001; Torgersen 2012). BPD commonly co-occurs with mood disorders, substance misuse, eating disorders, post-traumatic stress disorder (PTSD), attention-deficit hyperactivity disorder (ADHD), and is also associated with other personality disorders (Coid 2006; Lenzenweger 2007; Stepp 2012; Storebø 2014; Tomko 2014).

Although the short- to medium-term outcome of BPD is poor, there is some evidence that long-term follow-ups show a more favourable course, with remission rates of about 85% to 88%

within 10 years (Gunderson 2011b; Zanarini 2007). Here, however, remission only means that diagnostic criteria are not fulfilled and does not indicate the absence of any symptoms. Indeed, whereas acute symptoms - such as self-mutilation, help-seeking suicide threats or attempts and impulsivity - in most cases decrease with time, affective symptoms reflecting areas of chronic dysphoria, such as chronic feelings of emptiness, intense anger or profound abandonment, largely remain (Zanarini 2007). Therefore the majority of people with BPD still have significant levels of symptoms and experience severe and persistent impairment in social functioning (Kongerslev 2015; Ng 2016). Risk factors for a poorer long-term outcome are comorbid substance use disorders, PTSD, and anxiety cluster disorders (Zanarini 2005; Zanarini 2007), and also a family history of psychiatric disorder (especially mood disorders and substance use disorders), as well as demographic issues such as older age, longer treatment history, pathological childhood experiences, temperament issues, and adult psychosocial functioning (Chanen 2012; De Fruyt 2014; Kongerslev 2015; Zanarini 2007).

People with BPD have difficulties achieving and maintaining vocational and social functioning over time (Zanarini 2010). Furthermore treatment-seeking people with personality disorders, such as BPD, pose a high economic burden on society (van Asselt 2007). Effective treatments could potentially decrease the high costs associated with the condition (Soetmann 2008a). The problem of deliberate self-harm is also a particular issue within this group (Ayodeji 2015; Kongerslev 2015; Linehan 1997; Rossouw 2012). In medical settings, people with BPD often present after self-harming behaviour or in suicidal crisis and are treated in emergency settings, often involving repeated psychiatric hospitalisations (Bender 2006; Cailhol 2015).

In summary, BPD is a condition that has been extensively studied. It has a major impact on health facilities, as those affected often present in crisis. The recovery from symptoms or functional impairment (or both) was previously considered likely for only a low percentage of people diagnosed with BPD. However, the long-term course is better than what was previously assumed, due to more favourable symptomatic recoveries (Zanarini 2012). Nonetheless, people with BPD continue to have considerable interpersonal and functional problems, and sustainable recovery appears difficult to attain (Biskin 2015; Kongerslev 2015; Rossouw 2012).

## Description of the intervention

To date, all major treatment guidelines consider psychotherapy as the treatment of choice for BPD and assign drugs an adjunctive role (e.g. APA 2001; DGPPN 2009; Herpertz 2007; National Health and Medical Research Council 2013; NICE 2009). However, the large majority of people with BPD are prescribed psychotropic medications during the course of their illness. This may be the case in times of crisis, when people with BPD present to

mental health services with raised suicidality or parasuicidality, impulsivity-associated outbreaks, psychotic-like exacerbations, severe dissociations or aggravations of comorbid conditions (e.g. mood disorders), and when medications are used to achieve short-term stabilisation. Such crisis interventions will not be considered here but are subject to another Cochrane Review, which is currently being updated (Borschmann 2012).

In contrast to short-term crisis medication, up to 84.1% of people with BPD have been reported to use standing psychotropic medications (Bender 2001; Zanarini 2015), and as many as 92% have been reported to use any psychotropic medication for a non-specified period of time (Paton 2015). Indeed, it is a common finding that people with BPD are more likely to use psychotropic medications than people with other psychiatric conditions such as major depressive disorder (Bender 2001; Bender 2006), mood or anxiety disorders in general (Ansell 2007), or other personality disorders (Zanarini 2004a).

Studies across different countries show that antidepressants are the class of medication most often prescribed to BPD patients (Bender 2001; Knappich 2014; Makela 2006; Paton 2015; Sansone 2003; Zanarini 2015). Zanarini and colleagues found that 79.7% were taking antidepressant medication, followed by anxiolytics (46.6%), neuroleptics (38.6%), and mood stabilisers (35.9%) (Zanarini 2015). They also found that about 71% of people with BPD were using standing medications at six-year follow-up (Zanarini 2004a; Zanarini 2004b), and that they were still more likely to be using antidepressants, mood stabilisers, antipsychotics or anxiolytics than axis-II comparison participants at 16-year follow-up (Zanarini 2015). Polypharmacy is common, with reports of people with BPD taking, on average, 2.02 psychotropic medications at a time (Ansell 2007), and up to 28.6% taking four or more medications (Zanarini 2004a; Zanarini 2004b).

In summary, most BPD patients are taking psychotropic drugs for sustained periods of time, though medication is only regarded as an adjunctive to psychotherapy. Different classes of medication are used, with antidepressants being used most frequently, but there is no standard treatment. To date, any drug use in BPD is off-label (if not targeted at associated psychopathology such as depression or anxiety), but up to 82% of BPD patients without comorbid conditions receive pharmacotherapy to directly target BPD symptoms (Paton 2015).

## How the intervention might work

To date, there is broad consensus about no single drug being able to substantially 'treat' BPD itself (e.g. APA 2001; Biskin 2012; National Health and Medical Research Council 2013).

In fact, drug treatment options are chosen with the intent to ameliorate distinct symptoms or symptom clusters (also called 'symptom domains') that a certain person with BPD may experience. These may either be symptoms specific to BPD (i.e. as defined in the diagnostic criteria) or BPD-unspecific ones, such as depression

or anxiety, which are also common in BPD. A drug is mostly chosen due to its known efficacy in treating similar symptoms in other conditions (e.g. depression), or in conditions with putative similar underlying neurobiological features (e.g. impulsivity-related disorders). As a consequence, many different classes of drugs are used in BPD, depending on the individual clinical picture a person with BPD may experience (Bender 2001; National Health and Medical Research Council 2013; Zanarini 2015). As part of an integrated treatment plan, drug treatment may also be given with the intent to facilitate behaviourally-mediated learning processes as activated in a concurrent psychotherapy.

The rationale for using selective serotonin reuptake inhibitors in the treatment of BPD is that the serotonergic system has repeatedly been shown to be associated with low prefrontal serotonergic transmission in BPD (Herpertz 2007). The putative actions of atypical neuroleptics are also thought to impact the serotonergic system through a high 5HT1a receptor affinity and 5HT2a receptor antagonism. Therefore, atypical antipsychotics can be expected to have a stabilising effect on mood and anxiety, but also impulsivity and aggression (Herpertz 2007). Mood stabilisers are also used due to their stabilising effects on affective symptoms (Herpertz 2007). In recent years, omega-3 fatty acids (polyunsaturated fatty acids; PUFAs) have come into the focus of attention, as PUFAs deficiencies have been identified in many mental illnesses, and they have been assigned a role in impulsivity, mood and even suicidality (Gören 2011; Pompili 2017). Sedatives, such as benzodiazepines, are also commonly used in clinical practice with the intent to improve sleep, or decrease anxiety or agitation (Martinho 2014). However, the use of such agents is critical, due to their self-harming and addictive potential and also due to their well-known and unfavourable impact on learning processes as, for example, intended by psychotherapy (Hunter 2000; Westra 2002). And finally, the neuropeptide oxytocin has received attention in recent years, because oxytocin is supposed to lead to better emotion recognition and more trust in other people (Bakermans-Kranenburg 2013). It may, therefore, help people with BPD overcome hypersensitivity to perceived social threat (Meyer-Lindenberg 2011).

## Why it is important to do this review

BPD poses a major burden, both personal (Soetmann 2008b) and financial (Soetmann 2008a), on those directly affected and their relatives. In 2008, the US House of Representatives passed a House Resolution naming the month of May BPD Awareness Month (110th Congress 2007 to 2008). This underlines the large public health problem of BPD. Despite its frequent use in clinical practice, and research activities on this topic in the last three decades, any medication in BPD is off-label. All the more, patients and carers must be able to make informed decisions on the basis of the up-to-date evidence (Ingenhoven 2015; Paris 2015; Silk 2015). This Cochrane Review aims to systematically identify, investigate, and

integrate the current state of high-quality evidence on the topic of pharmacotherapy in BPD.

This is a new protocol for a new review, which will update and replace the Cochrane Review first published in 2010 (Stoffers 2010). As no published protocol seems to exist, we considered it necessary to write and publish a protocol before conducting this review. The Stoffers 2010 review came to the conclusion that the then available evidence indicated beneficial effects for some drugs (i.e. second-generation antipsychotics, mood stabilisers and omega-3 fatty acids), but that the overall quality of the evidence was not robust enough to draw any reliable conclusions. In the meantime research has continued in the field, and new findings may change findings of the previous review. Therefore an update of this review seems both appropriate and timely (Garner 2016).

## OBJECTIVES

To assess the beneficial and harmful effects of pharmacological treatment for adolescents and adults with borderline personality disorder (BPD).

## METHODS

### Criteria for considering studies for this review

#### Types of studies

Randomised controlled trials (RCTs).

#### Types of participants

Patients of all ages, in any setting, with a formal diagnosis of BPD according to the *Diagnostic and Statistical Manual of Mental Disorders* (DSM) Third Edition (DSM-III; APA 1980), Third Edition Revised (DSM-III R; APA 1987), Fourth Edition (DSM-IV; APA 1994), Fourth Edition Text Revision (DSM-IV-TR; APA 2000), and Fifth Edition (DSM-5; APA 2013)), with or without comorbid conditions.

We will require at least 70% of study participants to have a formal diagnosis of BPD. We will also include studies involving subsamples of BPD patients providing data on these patients are available separately. We will not include studies that focus on people with mental impairment, organic brain disorder, dementia, or other severe neurologic diseases, should there be any.

#### Types of interventions

Any drug or defined combination of drugs administered at any dosage, prescribed to treat the disorder or its symptoms, compared to a placebo or active comparator drug(s). We will include studies that pair drugs with an adjunctive intervention (e.g. psychological therapies), providing this is given to participants in both the intervention and control arm, and the pharmacological intervention is unique to the treatment group.

A drug must have been prescribed continuously for a minimum duration of two weeks for the study to be eligible for our review. In addition, we will judge the actual duration required for inclusion in light of the specific mode of action of the drug. Medication must have been used to treat the disorder or symptoms thereof.

#### Types of outcome measures

Outcomes can either be self-rated by patients or observer-rated by clinicians. We will include only adequately validated measures (plus spontaneous reporting of adverse events).

#### Primary outcomes

1. BPD severity, as assessed by, for example, the Zanarini Rating Scale for Borderline Personality Disorder (Zan-BPD; Zanarini 2003), the Borderline Personality Disorder Severity Index (BPDSI-IV; Arntz 2003), or the Clinical Global Impression Scale for Borderline Personality Disorder Patients (CGI-BPD; Perez 2007).
2. Self-harm, in terms of the proportion of participants with self-harming behaviour, or as assessed by, for example, the Deliberate Self-harm Inventory (DSHI; Gratz 2001) or the Self-harm Behavior Questionnaire (SHBQ; Gutierrez 2001).
3. Suicide-related outcomes, as assessed by, for example, the Suicidal Behaviours Questionnaire (SBQ; Osman 2001) or the Beck Scale for Suicidal Ideation (BSSI; Beck 1979) or in terms of the proportion of patients with suicidal acts.
4. Functioning, as assessed by, for example, the Global Assessment Scale (GAS; Endicott 1976), the Global Assessment of Functioning Scale (GAF; APA 1987) or the Social Functioning Questionnaire (SFQ; Tyrer 2005).

#### Secondary outcomes

1. Anger, as assessed by, for example, the "Hostility" subscale of the Symptom Checklist-90-Revised (SCL-90-R; Derogatis 1994), or the State-Trait Anger Expression Inventory (STAXI; Spielberger 1988).
2. Affective instability, as assessed by, for example, the relevant item or subscale on the Zan-BPD (Zanarini 2003), CGI-BPD (Perez 2007) or BPDSI-IV (Arntz 2003).
3. Chronic feelings of emptiness, as assessed by, for example, the relevant item or subscale on the Zan-BPD (Zanarini 2003), CGI-BPD (Perez 2007) or BPDSI-IV (Arntz 2003).

4. Impulsivity, as assessed by, for example, the Barrett Impulsiveness Scale (BIS; [Barrett 1995](#)), or the Anger, Irritability and Assault Questionnaire (AIAQ; [Coccaro 1991](#)).

5. Interpersonal problems, as assessed by, for example, the Inventory of Interpersonal Problems (IIP; [Horowitz 1988](#)), or the relevant item or subscale of the Zan-BPD ([Zanarini 2003](#)), CGI-BPD ([Perez 2007](#)) or BPDSI-IV ([Arntz 2003](#)), or SCL-90-R ([Derogatis 1994](#)).

6. Abandonment, as assessed by, for example, the relevant item or subscale of the Zan-BPD ([Zanarini 2003](#)), CGI-BPD ([Perez 2007](#)) or BPDSI-IV ([Arntz 2003](#)).

7. Identity disturbance, as assessed by, for example, the relevant item or subscale of the Zan-BPD ([Zanarini 2003](#)), CGI-BPD ([Perez 2007](#)) or BPDSI-IV ([Arntz 2003](#)).

8. Dissociation and psychotic-like symptoms, as assessed by, for example, the Dissociative Experience Scale (DES; [Bernstein 1986](#)), or the Brief Psychiatric Rating Scale (BPRS; [Overall 1962](#)).

9. Depression, as assessed by, for example, the Beck Depression Inventory (BDI; [Beck 1961](#)), or the Montgomery Åsberg Depression Rating Scale (MADRS; [Montgomery 1979](#)).

10. Attrition, in terms of patients lost after randomisation in each group.

11. Adverse effects, as measured by use of standardised psychometric rating scales such as the Systematic Assessment for Treatment Emergent Events (SAFTEE; [Levine 1986](#)), laboratory values or spontaneous reporting.

## Search methods for identification of studies

### Electronic searches

We will search the electronic databases and trials registers listed below to identify relevant trials.

1. Cochrane Central Register of Controlled Trials (CENTRAL; current issue), in the Cochrane Library, which includes the Cochrane Developmental, Psychosocial and Learning Problems Specialised Register
2. MEDLINE Ovid (1948 onwards)
3. Embase Ovid (1980 onwards)
4. CINAHL EBSCOhost (Cumulative Index to Nursing and Allied Health Literature; 1980 onwards)
5. PsycINFO Ovid (1806 onwards)
6. ERIC EBSCOhost (Education Resources Information Center; 1966 onwards)
7. BIOSIS Previews Web of Science Clarivate Analytics (1969 onwards)
8. Web of Science Core Collection Clarivate Analytics (1900 onwards)
9. Sociological Abstracts ProQuest (1952 onwards)

10. LILACS (Latin American and Caribbean Health Science Information database; all available years; [lilacs.bvsalud.org/en](#))

11. OpenGrey ([www.opengrey.eu](#))

12. Copac National, Academic and Specialist Library Catalogue (COPAC; [copac.jisc.ac.uk](#))

13. ProQuest Dissertations and Theses A&I (1973 onwards)

14. DART Europe E-Theses Portal ([www.dart-europe.eu/basic-search.php](#))

15. Networked Digital Library of Theses and Dissertations (NDLTD; [www.ndltd.org](#))

16. Australian New Zealand Clinical Trials Registry (ANZCTR; [www.anzctr.org.au/BasicSearch.aspx](#))

17. ClinicalTrials.gov ([clinicaltrials.gov](#))

18. EU Clinical Trials Register ([www.clinicaltrialsregister.eu/ctr-search/search](#))

19. ISRCTN Registry ([www.isrctn.com](#))

20. UK Clinical Trials Gateway ([www.ukctg.nihr.ac.uk/#popoverSearchDivId](#))

21. WHO International Clinical Trials Registry Platform (ICTRP; [who.int/ictrp/en](#))

The search strategy for MEDLINE is in [Appendix 1](#) and we will modify it for other databases using the appropriate syntax and controlled terms. We will not limit our searches by language, year of publication, or type of publication. We will seek translation of the relevant sections of non-English language articles.

### Searching other resources

We will handsearch relevant journals including the Journal of Personality Disorders; the American Journal of Psychiatry; JAMA Psychiatry; British Journal of Psychiatry; ACTA Psychiatrica Scandinavica; Journal of the American Academy of Child and Adolescent Psychiatry; Personality Disorders: Theory, Research and Treatment; and the Journal of Clinical Psychiatry. Additionally, we will contact researchers working in the field by email, to ask for unpublished data. We will also trace cross-references from relevant literature. Finally, we will search for unpublished data on the websites of the United States Food and Drug Administration (FDA; [www.fda.gov](#)) and the European Medicines Agency (EMA; [www.ema.europa.eu/ema](#)).

### Data collection and analysis

We will conduct this review according to guidelines set out in the *Cochrane Handbook for Systematic Reviews of Interventions* ([Higgins 2011a](#)), and perform the analyses using the latest version of Review Manager 5 (RevMan 5), Cochrane's statistical software ([Review Manager 2014](#)).

### Selection of studies

Six review authors (JMSW, OJS, BAV, MLK, JTM, SSN) will work in three pairs and independently screen titles and abstracts of all records retrieved by the searches; we will resolve uncertainty or disagreement by consensus. For records that could be eligible RCTs, we will obtain the full-text report and assess it for eligibility based on the inclusion criteria ([Criteria for considering studies for this review](#)). Review authors will discuss disagreements, and if they cannot reach an agreement they will consult a third review author (ES or KL). We will list apparently relevant RCTs that do not fulfil the inclusion criteria with reasons for exclusion in the 'Characteristics of excluded studies' tables. We will use [Covidence software](#) to keep track of appraised trials and decisions. To ensure transparency of study selection, we will provide a flow chart in accordance with the PRISMA statement, to show how many records have been excluded and for what reason ([Moher 1999](#)).

### Data extraction and management

All review authors will extract data. Review authors will work in pairs and will complete the data collection form independently to ensure accuracy. We will resolve disagreements by discussion or use an arbiter (ES) if required. JMSW and OJS will enter the data into RevMan 5 ([Review Manager 2014](#)). In those cases where there are not enough data or data are unclear in the published trial reports, we will contact the trial authors, requesting them to supply the missing information. We will develop data extraction forms to facilitate standardisation of data extraction.

### Assessment of risk of bias in included studies

All review authors will assess the risk of bias using Cochrane's tool for assessing risk of bias ([Higgins 2017](#)). For each included trial, data extractors will independently evaluate each risk of bias domain - [Appendix 4](#) - as being at low, unclear (uncertain) or high risk of bias, resolving disagreements by discussion. We will categorise trials that have a low risk of bias in all domains at low risk of bias overall, and we will consider trials with one or more unclear or high risk of bias domains as trials at high risk of bias overall. Given the risk of overestimation of beneficial intervention effects and underestimation of harmful intervention effects in RCTs with unclear or inadequate methodological quality ([Kjaergard 2001](#); [Lundh 2012](#); [Moher 1998](#); [Savović 2012a](#); [Savović 2012b](#); [Schulz 1995](#); [Wood 2008](#)), we will assess the influence of risk of bias on our results (see [Sensitivity analysis](#)).

### Measures of treatment effect

#### Dichotomous data

We will summarise dichotomous data as risk ratios (RRs) with 95% confidence intervals (CIs). We will calculate the risk difference (RD) and the number needed to treat for an additional beneficial

outcome (NNTB) or for an additional harmful outcome (NNTH) if there is a significant effect of the intervention.

#### Continuous data

For continuous data, we will compare the mean score between the two groups to give a mean difference (MD) and present this with 95% CIs. We will use the overall MD, where possible, to compare the outcome measures from trials. We will estimate the standardised MD (SMD) where different outcome measures are used to measure the same construct in the trials. We will calculate SMDs using end-scores at post-treatment results and, in a separate analysis, follow-up data. We will bundle follow-up data in six-month steps. Where the direction of a scale is opposite to most of the other scales, we will multiply the corresponding mean values by  $-1$  to ensure adjusted values. If the trials do not report means and standard deviations but report other values like t-tests and P values, we will try to transform these into standard deviations.

Our first choice will be to calculate effect sizes on the basis of intention-to-treat (ITT) data. If means and standard deviations from an ITT analysis and missing values that were replaced are available, we will use these data. In other cases, we will conduct the analysis using only the available data.

We will perform all calculations using the latest release of RevMan 5 software ([Review Manager 2014](#)).

### Unit of analysis issues

#### Repeated observations

We will calculate study estimates on the basis of post-treatment group results. We will conduct separate analyses for data from different points of measurement (i.e. we will use the last measurement where post-treatment follow-up data at six-month intervals is available). We will not use interim observations.

#### Cluster-randomised trials

Where trials have used cluster randomisation, we anticipate that investigators will have presented their results after appropriately controlling for clustering effects (robust standard errors or hierarchical linear models). If it is unclear whether a cluster-randomised trial has used appropriate controls for clustering, we will contact the investigators for further information. Where appropriate controls have not been used, we will request and reanalyse individual participant data using multilevel models that control for clustering. If individual participant data are not available, we will look for information on intraclass correlation coefficients to adjust for the potential clustering effects. Following this, we will analyse effect sizes and standard errors in RevMan 5 ([Review Manager 2014](#)),



using the generic inverse method (Higgins 2011b). If there is insufficient information to control for clustering, we will enter outcome data into RevMan 5 (Review Manager 2014), using individuals as the units of analysis, and conduct a sensitivity analysis to assess the potential biasing effects of inadequately controlled cluster-randomised trials (Donner 2002); see [Sensitivity analysis](#).

### Cross-over trials

We plan to include data from randomised cross-over studies up to the point of first cross-over (first period only) (Curtin 2002). We will not consider outcomes from subsequent periods due to the likelihood of carry-over effects from the preceding treatment(s). We will not combine repeated observations on participants in one meta-analysis.

### Studies with multiple treatment groups

If a trial compares more than two intervention groups, we will include all pair-wise comparisons as long as they are not subject to the same meta-analysis. If a trial includes two arms of different doses of a certain drug that are tested against placebo, we will combine the experimental groups into a single group, as recommended in the *Cochrane Handbook for Systematic Reviews of Interventions*, making a single, pair-wise comparison (Higgins 2011b). Thus we will avoid including the same group of participants twice in the same meta-analysis.

### Adjustment for multiplicity

We will adjust the P values and CIs for multiplicity due to the many secondary outcome comparisons following the method described by Jakobsen 2014b.

### Dealing with missing data

We will try to obtain any missing data, including incomplete outcome data, by contacting trial authors. We will report this information in the 'Risk of bias' tables.

We will evaluate the methods used to handle the missing data in the publications and to what extent it was likely that the missing data influenced the results of outcomes of interest. For preference, we will calculate effect sizes on the basis of ITT data. If only available data are reported, we will calculate effect sizes on this basis. Where dichotomous data are not presented on the basis of ITT data, we will add the number of participants lost in each group to the participants with unfavourable results, acting on the assumption that most patients with BPD do not get lost at random. For continuous outcomes, we will discuss each trial's methodology for dealing with missing continuous data (e.g. last observation carried forward or modified ITT approach). We will use per protocol analysis, as available from the trial reports (that is, results are based on the number of patients at follow-up).

If data are not reported in an immediately usable way, we will consult a statistician.

We will assess results derived from statistically processed data in sensitivity analyses. See [Sensitivity analysis](#).

### Assessment of heterogeneity

We will assess studies for clinical homogeneity with respect to type of pharmacological interventions, setting and control groups. We will take into account the number of studies and study characteristics, such as duration, dose and participants, to judge if heterogeneity is more probable due to clinical (i.e. explainable factors) or to unknown factors. In case of substantial heterogeneity, we will make up subgroups according to study characteristics, such as study size, duration, dose or participants, and discuss the most apparent sources of heterogeneity. We will evaluate methodological heterogeneity by comparing the design of trials. See [Subgroup analysis and investigation of heterogeneity](#).

We will investigate statistical heterogeneity within a certain comparison by visual inspection of the graphs and the  $I^2$  statistic (Higgins 2003). We will judge  $I^2$  values between 0% and 40% to indicate little heterogeneity, between 30% and 60% to indicate moderate heterogeneity, between 50% and 90% to indicate substantial heterogeneity, and between 75% and 100% to indicate considerable heterogeneity (Deeks 2017). We will also assess

statistical heterogeneity by  $\text{Chi}^2$  test ( $P < 0.10$ ) and  $\tau^2$  - an estimate of between-study variability.

### Assessment of reporting biases

We will provide funnel plots for comparisons with sufficient primary studies and we will perform Egger's statistical test for small-study effects (Egger 1997). We will not use a visual inspection of the funnel plot if there are fewer than 10 studies in the meta-analysis, as recommended in the *Cochrane Handbook for Systematic Reviews of Interventions* (Sterne 2017).

### Data synthesis

We will perform statistical analyses according to recommendations in the latest version of the *Cochrane Handbook for Systematic Reviews of Interventions* (Deeks 2017). In carrying out the meta-analysis we will use the inverse-variance method, in order to give more weight to more precise estimates from studies with less variance (mostly larger studies). We will divide the doses and the controls into different comparisons, ensuring that the treatment comparisons are comparable and homogeneous. We will use the random-effects model for meta-analysis, since we expect some degree of clinical heterogeneity to be present in most cases, though not so substantial as to prevent pooling in principle. For trials with a high level of statistical heterogeneity, and where the amount of clinical heterogeneity makes it inappropriate to use these trials in

meta-analyses, we will provide a narrative description of the trial results. If we consider data pooling to be feasible, we will pool the primary studies effects and calculate their 95% CIs. If a trial provides more than one measure for the same outcome construct (e.g. several questionnaires for the assessment of depression), we will select the one used most often in the whole pool of included studies for effect size calculation, in order to minimise heterogeneity of outcomes in form and content. If a study reports data of two assessment instruments that are equally frequently used, two review authors will discuss the issue and choose the one which is, in its content, most appropriate for assessing BPD patients. We will prefer observer-rated measures as the primary analysis.

### Subgroup analysis and investigation of heterogeneity

We will conduct a subgroup analysis to make hypotheses about the subgroups mentioned below.

1. Age (15 to under 18 years of age, 18 to 50 years of age, above 50 years of age)
2. Sex (male versus female)
3. Comorbidity (patients with comorbidity versus patients without comorbidity)
4. Doses
5. Different setting (outpatient compared to inpatient)
6. Differences between different types of medication within the same class (for example, antipsychotic, antidepressant)

### Heterogeneity-adjusted required information size and Trial Sequential Analysis

Trial Sequential Analysis (TSA) is a methodology that combines a required information size (RIS) calculation for a meta-analysis with the threshold for statistical significance (Brok 2008; Brok 2009; Thorlund 2009; Wetterslev 2008). TSA is a tool for quantifying the statistical reliability of the data in cumulative meta-analysis, adjusting P values for sparse data and for repetitive testing on accumulating data (Brok 2008; Brok 2009; Thorlund 2009; Wetterslev 2008).

Comparable to the a priori sample size estimation in a single randomised trial, a meta-analysis should include a RIS calculation at least as large as the sample size of an adequately powered single trial to reduce the risk of random error. TSA calculates the RIS in a meta-analysis and provides an alpha-spending boundary to adjust the significance level for sparse data and repetitive testing on accumulating data (CTU 2011; Wetterslev 2008), and consequently the risk of random error can be assessed. Multiple analysis of accumulating data when new trials emerge leads to repeated significant testing and hence introduces multiplicity, thus use of a conventional P value is prone to exacerbate the risk of random error (Berkey 1996; Lau 1995). Meta-analyses not reaching the RIS are analysed with trial sequential alpha-spending monitoring boundaries analogous to interim monitoring boundaries in a sin-

gle trial (Wetterslev 2008). This approach will be crucial in future updates of the review. We will calculate an RIS on all outcomes in the review. If a TSA does not reveal significant findings (no crossing of the alpha-spending boundary and no crossing of the conventional boundary of  $P = 0.05$ ) before the RIS has been reached, then the conclusion should either be that more trials are needed to reject or accept an intervention effect that was used for calculation of the required sample size or - in the case when the cumulated Z-curve enters the futility area - the anticipated effect can be rejected. We will calculate the a priori diversity-adjusted required information size (that is, number of patients required to detect or reject a specific intervention effect in the meta-analysis), and perform a TSA for the primary outcomes based on the following a priori assumptions.

1. The standard deviation of the primary outcome is 1.0.
2. An anticipated intervention effect equal to Hedge's  $g$  of 0.5.
3. A maximum type I error of 5% ( $\alpha$ ).
4. A maximum type II error of 20% ( $\beta$ ; equal to a minimum 80% power).
5. A priori anticipated 50% diversity (Brok 2008; Brok 2009; Thorlund 2009; Wetterslev 2008; Wetterslev 2009).

We will also calculate a post hoc, low bias, risk diversity-adjusted required information size (that is, the number of patients required to detect or reject a specific intervention effect in the meta-analysis), and perform a TSA for the primary outcomes based on the following estimated assumptions.

1. The standard deviation of the primary outcome in patients in the control group of trials with low risk of bias.
2. The estimated intervention effect in trials with low risk of bias.
3. A maximum type I error of 5% ( $\alpha$ ).
4. A maximum type II error of 20% ( $\beta$ ; equal to a minimum 80% power).
5. The estimated diversity in the trials included in the meta-analysis (Brok 2008; Brok 2009; Thorlund 2009; Wetterslev 2008).

### 'Summary of findings' tables

We will use the GRADE approach to construct a 'Summary of findings' table in which to document all review outcomes. The GRADE approach appraises the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. Considerations are due to: within-trial risk of bias; directness of the evidence; heterogeneity of the data; precision of effect estimates; and risk of publication bias (Andrews 2013a; Andrews 2013b; Balshem 2011; Brunetti 2013; Guyatt 2011a; Guyatt 2011b; Guyatt 2011c; Guyatt 2011d; Guyatt 2011e; Guyatt 2011f; Guyatt 2011g; Guyatt 2011h; Guyatt 2013a; Guyatt 2013b; Guyatt 2013c; Mustafa 2013). When possible, we will use the MD or the RR, and we will use Trial Sequential Analysis (TSA) to rate

the imprecision (Jakobsen 2014a). We will report the four primary outcomes (BPD severity, self-harm, suicide-related outcomes, and mental health status) and the three secondary outcomes (interpersonal problems, attrition, and adverse events) in the 'Summary of findings' table for the main comparison (Atkins 2004).

### Sensitivity analysis

We will assess the impact of heterogeneity on the overall pooled effect estimate by removing studies ('outliers') that are contributing to the heterogeneity. We will remove outliers one by one and assess the impact on the overall outcome.

We will conduct sensitivity analyses to determine whether findings are sensitive to the following.

1. Decisions made during the review process (such as our assessment of the level of clinical heterogeneity).
2. Impact of bias (studies with low and high risk of bias).
3. Type of model used for analysis (repeating the analysis using the fixed-effect model to test the robustness of the results).
4. Type of data collection (for example, different ways to measure adverse events).
5. Imputed data (comparing the analyses with available outcome data with those using the intention-to-treat (ITT)

approach).

## ACKNOWLEDGEMENTS

We thank the Cochrane Developmental, Psychosocial and Learning Problems (CDPLP) Editorial Team, Joanne Wilson (Managing Editor), Margaret Anderson (Information Specialist), and Geraldine Macdonald (Coordinating Editor).

We are grateful to the German Cochrane Centre for supporting this work. We are especially grateful to Gerd Antes, Director of the German Cochrane Centre, who initially made contact with CDPLP and helped in gaining grants for financing this work.

We are also grateful to Martin Schumacher, Director of the Institute of Biostatistics and Medical Informatics at the University Medical Center Freiburg, who gave support in application submission.

In addition, thanks to research librarian Trine Lacoppidan Kæstel for writing the search strategy.

Finally, we are grateful to the German Ministry of Education and Research for supporting this work.

## REFERENCES

### Additional references

#### Akiskal 2004

Akiskal HS. Demystifying borderline personality: critique of the concept and unorthodox reflections on its natural kinship with the bipolar spectrum. *Acta Psychiatrica Scandinavica* 2004;**110**(6):401–7. [DOI: 10.1111/j.1600-0447.2004.00461.x; PUBMED: PMID: 15521823]

#### Andrews 2013a

Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. *Journal of Clinical Epidemiology* 2013;**66**(7):719–25. [DOI: 10.1016/j.jclinepi.2012.03.013; PUBMED: 23312392]

#### Andrews 2013b

Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15. Going from evidence to recommendation - determinants of a recommendation's direction and strength. *Journal of Clinical Epidemiology* 2013;**66**(7):726–35. [DOI: 10.1016/j.jclinepi.2013.02.003; PUBMED: 23570745]

#### Ansell 2007

Ansell EB, Sanislow CA, McGlashan TH, Grilo CM. Psychosocial impairment and treatment utilization by patients with borderline personality disorder, other

personality disorders, mood and anxiety disorders, and a healthy comparison group. *Comprehensive Psychiatry* 2007;**48**(4):329–36. [DOI: 10.1016/j.comppsy.2007.02.001; PUBMED: 17560953]

#### APA 1980

American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (DSM-III)*. 3rd Edition. Washington (DC): American Psychiatric Association, 1980. [ISBN 978–0–89042–0416]

#### APA 1987

American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R)*. 3rd Edition. Washington (DC): American Psychiatric Association, 1987. [ISBN 978–0–89042–0195]

#### APA 1994

American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)*. 4th Edition. Washington (DC): American Psychiatric Association, 1994. [ISBN 978–0–89042–0610]

#### APA 2000

American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)*. 4th Edition. Washington (DC): American Psychiatric Association, 2000. [ISBN 978–0–89042–0256]

**APA 2001**

American Psychiatric Association. Practice guideline for the treatment of patients with borderline personality disorder. *The American Journal of Psychiatry* 2001;**158**(10 Suppl): 1–52. [PUBMED: 11665545]

**APA 2013**

American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (DSM-5)*. 5. Washington (DC): American Psychiatric Association, 2013. [ISBN 978–0–89042–554–1]

**Arntz 2003**

Arntz A, van den Hoorn M, Cornelis J, Verheul R, van den Bosch W, de Bie AJHT. Reliability and validity of the borderline personality disorder severity index. *Journal of Personality Disorders* 2003;**17**(1):45–59. [PUBMED: 12659546]

**Atkins 2004**

Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. *BMJ* 2004;**328**(7454):1490–9. [DOI: 10.1136/bmj.328.7454.1490; PMC428525; PUBMED: 15205295]

**Ayodeji 2015**

Ayodeji E, Green J, Roberts C, Trainor G, Rothwell J, Woodham A, et al. The influence of personality disorder on outcome in adolescent self-harm. *The British Journal of Psychiatry* 2015;**207**(4):313–9. [DOI: 10.1192/bjp.bp.113.138941; PUBMED: 26250743]

**Bakermans-Kranenburg 2013**

Bakermans-Kranenburg MJ, van I Jzendoorn MH. Sniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy. *Translational Psychiatry* 2013;**3**(5):e258. [DOI: 10.1038/tp.2013.34; PMC3669921; PUBMED: 23695233]

**Balshem 2011**

Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. *Journal of Clinical Epidemiology* 2011;**64**(4):401–6. [DOI: 10.1016/j.jclinepi.2010.07.015; PUBMED: 21208779]

**Barrett 1995**

Barrett ES, Stanford MS. Impulsiveness. In: Costello CG editor(s). *Personality Characteristics of the Personality Disordered*. New York (NY): Wiley, 1995:91–118. [ISBN 978–0–471–01529–1]

**Beck 1961**

Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. *Archives of General Psychiatry* 1961;**4**:561–71. [PUBMED: 13688369]

**Beck 1979**

Beck AT, Kovacs M, Weissman A. The assessment of suicidal intention: the Scale for Suicide Ideation. *Journal of Consulting and Clinical Psychology* 1979;**47**(2):343–52. [PUBMED: 469082]

**Bender 2001**

Bender DS, Dolan RT, Skodol AE, Sanislow CA, Dyck IR, McGlashan TH, et al. Treatment utilization by patients with personality disorders. *The American Journal of Psychiatry* 2001;**158**(2):295–302. [DOI: 10.1176/appi.ajp.158.2.295; PUBMED: 11156814]

**Bender 2006**

Bender DS, Skodol AE, Pagano ME, Dyck IE, Grilo CM, Shea MT, et al. Prospective assessment of treatment use by patients with personality disorders. *Psychiatric Services* 2006;**57**(2):254–7. [DOI: 10.1176/appi.ps.57.2.254; PMC2705621; PUBMED: 16452705]

**Berkey 1996**

Berkey CS, Mosteller F, Lau J, Antman E. Uncertainty of the time of first significance in random effects cumulative meta-analysis. *Controlled Clinical Trials* 1996;**17**(5): 357–71. [PUBMED: 8932970]

**Bernstein 1986**

Bernstein EM, Putnam FW. Development, reliability, and validity of a dissociation scale. *Journal of Nervous and Mental Disease* 1986;**174**(12):727–35. [PUBMED: 3783140]

**Bero 2013**

Bero L. Why the Cochrane risk of bias tool should include funding source as a standard item. *Cochrane Database of Systematic Reviews* 2013, issue 12:ED000075. [DOI: 10.1002/14651858.ED000075; PUBMED: 24575439]

**Biskin 2012**

Biskin RS, Paris J. Management of borderline personality disorder. *CMAJ* 2012;**184**(17):1897–902. [DOI: 10.1503/cmaj.112055]

**Biskin 2015**

Biskin RS. The lifetime course of borderline personality disorder. *Canadian Journal of Psychiatry* 2015;**60**(7):303–8. [DOI: 10.1177/070674371506000702; PMC4500179; PUBMED: 26175388]

**Black 2004**

Black DW, Blum N, Pfohl B, Hale N. Suicidal behavior in borderline personality disorder: prevalence, risk factors, prediction, and prevention. *Journal of Personality Disorders* 2004;**18**(3):226–39. [DOI: 10.1521/pedi.18.3.226.35445; PUBMED: 15237043]

**Borschmann 2012**

Borschmann R, Henderson C, Hogg J, Phillips R, Moran P. Crisis interventions for people with borderline personality disorder. *Cochrane Database of Systematic Reviews* 2012, Issue 6. [DOI: 10.1002/14651858.CD009353.pub2; PUBMED: 22696385]

**Brok 2008**

Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. *Journal of Clinical Epidemiology* 2008;**61**(8):763–9. [DOI: 10.1016/j.jclinepi.2007.10.007; PUBMED: 18411040]

**Brok 2009**

Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analysis may be inconclusive -- trial

- sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. *International Journal of Epidemiology* 2009;**38**(1):287–98. [DOI: 10.1093/ije/dyn188; PUBMED: 18824466]
- Brunetti 2013**  
Brunetti M, Shemilt I, Pregno S, Vale L, Oxman AD, Lord J, et al. GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence. *Journal of Clinical Epidemiology* 2013;**66**(2):140–50. [DOI: 10.1016/j.jclinepi.2012.04.012; PUBMED: 22863410]
- Cailhol 2015**  
Cailhol L, Thalamas C, Garrido C, Birmes P, Lapeyre-Mestre M. Mental health service utilization among borderline personality disorder patients inpatient [Utilisation des services de soin par les patients hospitalisés, présentant un trouble de personnalité borderline en Midi-Pyrénées]. *L'Encéphale* 2015;**41**(2):115–22. [DOI: 10.1016/j.encep.2014.10.008; PUBMED: 25526809]
- Chanen 2012**  
Chanen AM, Kaess M. Developmental pathways to borderline personality disorder. *Current Psychiatry Reports* 2012;**14**(1):45–53. [DOI: 10.1007/s11920-011-0242-y; PUBMED: 22009682]
- Coccaro 1991**  
Coccaro EF, Harvey PD, Kupsaw-Lawrence E, Herbert JL, Bernstein DP. Development of neuropharmacologically-based behavioral assessments of impulsive aggressive behavior. *Journal of Neuropsychiatry and Clinical Neurosciences* 1991;**3**(2):S44–S51. [PUBMED: 1821222]
- Coid 2006**  
Coid J, Yang M, Tyrer P, Roberts A, Ullrich S. Prevalence and correlates of personality disorder in Great Britain. *British Journal of Psychiatry* 2006;**188**:423–31. [DOI: 10.1192/bjp.188.5.423; PUBMED: 16648528]
- CTU 2011**  
Copenhagen Trial Unit. TSA - Trial Sequential Analysis. www.ctu.dk/tsa (accessed 12 December 2016).
- Curtin 2002**  
Curtin F, Elbourne D, Altman DG. Meta-analysis combining parallel and cross-over clinical trials. III: the issue of carry-over. *Statistics in Medicine* 2002;**21**(15): 2161–73. [DOI: 10.1002/sim.1207; PUBMED: 12210631]
- De Fruyt 2014**  
De Fruyt F, De Clercq B. Antecedents of personality disorder in childhood and adolescence: toward an integrative developmental model. *Annual Review of Clinical Psychology* 2014;**10**:449–76. [DOI: 10.1146/annurev-clinpsy-032813-15364; PUBMED: 24471374]
- Deeks 2017**  
Deeks JJ, Higgins JPT, Altman SD, editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook.
- Derogatis 1994**  
Derogatis LR, Lazarus L. SCL-90-R, Brief Symptom Inventory, and matching clinical rating scales. In: Maruish ME editor(s). *The Use of Psychological Testing for Treatment Planning and Outcome Assessment*. 1st Edition. Hillsdale (NJ): Lawrence Erlbaum Associates, 1994. [ISBN 978-0-80581-1629]
- DGPPN 2009**  
Deutsche Gesellschaft für Psychiatrie und Psychotherapie Psychosomatik und Nervenheilkunde (DGPPN) [German Association for Psychiatry, Psychotherapy, Psychosomatics]. *S2-Praxisleitlinien in Psychiatrie und Psychotherapie. Band 1: Behandlungsleitlinie Persönlichkeitsstörungen [S2 Practical Guidelines in Psychiatry and Psychotherapy. Volume 1: Treatment Guideline Personality Disorders]*. Heidelberg (DE): Steinkopff Verlag, 2009. [ISBN 978-3-7985-1853-7]
- Donner 2002**  
Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. *Statistics in Medicine* 2002;**21**(19): 2971–80. [DOI: 10.1002/sim.1301; PUBMED: 12325113]
- Doyle 2016**  
Doyle M, While D, Mok PL, Windfuhr K, Ashcroft DM, Kontopantelis E, et al. Suicide risk in primary care patients diagnosed with a personality disorder: a nested case control study. *BMC Family Practice* 2016;**17**:106. [DOI: doi.org/10.1186/s12875-016-0479-y; PMC4974738; PUBMED: 27495284]
- Endicott 1976**  
Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global assessment scale: a procedure for measuring overall severity of psychiatric disturbance. *Archives of General Psychiatry* 1976;**33**(6):766–71. [PUBMED: 938196]
- Fonagy 2009**  
Fonagy P, Luyten P. A developmental, mentalization-based approach to the understanding and treatment of borderline personality disorder. *Development and Psychopathology* 2009;**21**(4):1355–81. [DOI: 10.1017/S0954579409990198; PUBMED: 19825272]
- Garner 2016**  
Garner P, Hopewell S, Chandler J, MacLehose H, Schünemann HJ, Akl EA, et al. When and how to update systematic reviews: consensus and checklist. *BMJ* 2016;**354**:i3507. [PMC4955793; PUBMED: 27443385]
- Goodman 2012**  
Goodman M, Roiff T, Oakes AH, Paris J. Suicidal risk and management in borderline personality disorder. *Current Psychiatry Reports* 2012;**14**(1):79–85. [DOI: 10.1007/s11920-011-0249-4; PUBMED: 22113831]
- Gratz 2001**  
Gratz KL. Measurement of deliberate self-harm: preliminary data on the deliberate self-harm inventory. *Journal of Psychopathology and Behavioral Assessment* 2001;**23**(4): 253–63. [DOI: 10.1023/A:1012779403943]

**Gunderson 2009**

Gunderson JG. Borderline personality disorder: ontogeny of a diagnosis. *American Journal of Psychiatry* 2009;**166**(5):530–9. [DOI: 10.1176/appi.ajp.2009.08121825; NIHMS313194; PMC3145201]

**Gunderson 2011a**

Gunderson JG. Borderline personality disorder. *New England Journal of Medicine* 2011;**364**(21):2037–42. [DOI: 10.1056/NEJMc1007358]

**Gunderson 2011b**

Gunderson JG, Stout RL, McGlashan TH, Shea MT, Morey LC, Grilo CM, et al. Ten-year course of borderline personality disorder: psychopathology and function from the Collaborative Longitudinal Personality Disorders study. *Archives of General Psychiatry* 2011;**68**(8):827–37. [DOI: 10.1001/archgenpsychiatry.2011.37; PMC3158489; PUBMED: 21464343]

**Guttierrez 2001**

Guttierrez PM, Osman A, Barrios FX, Kopper BA. Development and initial validation of the Self-Harm Behavior Questionnaire. *Journal of Personality Assessment* 2001;**77**(3):475–90. [DOI: 10.1207/S15327752JPA7703\_08; PUBMED: 11781034]

**Guyatt 2011a**

Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. *Journal of Clinical Epidemiology* 2011;**64**(4):383–94. [DOI: 10.1016/j.jclinepi.2010.04.026; PUBMED: 21195583]

**Guyatt 2011b**

Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. *Journal of Clinical Epidemiology* 2011;**64**(4):395–400. [DOI: 10.1016/j.jclinepi.2010.09.012; PUBMED: 21194891]

**Guyatt 2011c**

Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence -- study limitations (risk of bias). *Journal of Clinical Epidemiology* 2011;**64**(4):407–15. [DOI: 10.1016/j.jclinepi.2010.07.017; PUBMED: 21247734]

**Guyatt 2011d**

Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence -- publication bias. *Journal of Clinical Epidemiology* 2011;**64**(12):1277–82. [DOI: 10.1016/j.jclinepi.2011.01.011; PUBMED: 21802904]

**Guyatt 2011e**

Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence -- imprecision. *Journal of Clinical Epidemiology* 2011;**64**(12):1283–93. [DOI: 10.1016/j.jclinepi.2011.01.012; PUBMED: 21839614]

**Guyatt 2011f**

Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the

quality of evidence -- inconsistency. *Journal of Clinical Epidemiology* 2011;**64**(12):1294–302. [DOI: 10.1016/j.jclinepi.2011.03.017; PUBMED: 21803546]

**Guyatt 2011g**

Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence -- indirectness. *Journal of Clinical Epidemiology* 2011;**64**(12):1303–10. [DOI: 10.1016/j.jclinepi.2011.04.014; PUBMED: 21802903]

**Guyatt 2011h**

Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. *Journal of Clinical Epidemiology* 2011;**64**(12):1311–6. [DOI: 10.1016/j.jclinepi.2011.06.004; PUBMED: 21802902]

**Guyatt 2013a**

Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. *Journal of Clinical Epidemiology* 2013;**66**(2):151–7. [DOI: 10.1016/j.jclinepi.2012.01.006; PUBMED: 22542023]

**Guyatt 2013b**

Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables - binary outcomes. *Journal of Clinical Epidemiology* 2013;**66**(2):158–72. [DOI: 10.1016/j.jclinepi.2012.01.012; PUBMED: 22609141]

**Guyatt 2013c**

Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles - continuous outcomes. *Journal of Clinical Epidemiology* 2013;**66**(2):173–83. [DOI: 10.1016/j.jclinepi.2012.08.001; PUBMED: 23116689]

**Gören 2011**

Gören JL, Tewksbury AT. The use of omega-3 fatty acids in mental illness. *Journal of Pharmacy Practice* 2011;**24**(5):452–71. [DOI: 10.1177/0897190011422876]

**Gotzsche 2015**

Gotzsche P. Re: Why the Cochrane risk of bias tool should include funding source as a standard item. Response to JAC Sterne. [www.cochranelibrary.com/editorial/10.1002/14651858.ED000076](http://www.cochranelibrary.com/editorial/10.1002/14651858.ED000076) (accessed 19 January 2018).

**Herpertz 2007**

Herpertz SC, Zanarini M, Schulz CS, Siever L, Lieb K, Möller H-J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. *The World Journal of Biological Psychiatry* 2007;**8**(4):212–44. [DOI: 10.1080/15622970701685224; PUBMED: 17963189]

**Higgins 2003**

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**(7414):557–60. [DOI: 10.1136/bmj.327.7414.557; PMC192859; PUBMED: 12958120]

**Higgins 2011a**

Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from [handbook.cochrane.org](http://handbook.cochrane.org).

**Higgins 2011b**

Higgins JPT, Deeks JJ, Altman DG, editor(s). Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from [handbook.cochrane.org](http://handbook.cochrane.org).

**Higgins 2017**

Higgins JPT, Altman DG, Sterne JAC, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston M, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).

**Horowitz 1988**

Horowitz LM, Rosenberg SE, Baer BA, Ureño G, Villaseñor VS. Inventory of interpersonal problems: psychometric properties and clinical applications. *Journal of Consulting and Clinical Psychology* 1988;**56**(6):885–92. [PUBMED: 3204198]

**Hunter 2000**

Hunter RH. Treatment, management, and control: improving outcomes through more treatment and less control. *New Directions for Mental Health Services* 2000;**88**: 5–15. [DOI: 10.1002/yd.23320008803]

**Hörz 2010**

Hörz S, Zanarini MC, Frankenburg FR, Reich DB, Fitzmaurice G. Ten-year use of mental health services by patients with borderline personality disorder and with other axis II disorders. *Psychiatric Services* 2010;**61**(6): 612–6. [DOI: 10.1176/ps.2010.61.6.612; PMC3889171; PUBMED: 20513685]

**Ingenhoven 2015**

Ingenhoven T. Pharmacotherapy for borderline patients: business as usual or by default?. *Journal of Clinical Psychiatry* 2015;**76**(4):e522–3. [DOI: 10.4088/JCP.14com09522; PUBMED: 25919847]

**Jakobsen 2014a**

Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. *BMC Medical Research Methodology* 2014;**14**:120. [DOI: 10.1186/1471-2288-14-120; PMC4251848; PUBMED: 25416419]

**Jakobsen 2014b**

Jakobsen JC, Gluud C, Winkel P, Lange T, Wetterslev J. The thresholds for statistical and clinical significance - a five-step procedure for evaluation of intervention effects in randomised clinical trials. *BMC Medical Research Methodology* 2014;**14**:34. [DOI: 10.1186/1471-2288-14-34; PMC4015863; PUBMED: 24588900]

**Kernberg 1967**

Kernberg O. Borderline Personality Organization. *Journal of the American Psychoanalytic Association* 1967;**15**(3):641–85. [DOI: doi:10.1177/000306516701500309.; PUBMED: 4861171]

**Kernberg 1975**

Kernberg OF. *Borderline Conditions and Primary Narcissism*. New York (NY): Jason Aronson, Inc., 1975.

**Kjaergard 2001**

Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. *Annals of Internal Medicine* 2001;**135**(11):982–9. [PUBMED: 11730399]

**Knappich 2014**

Knappich M, Hörz-Sagstetter S, Scherwethöffer D, Leucht S, Rentrop M. Pharmacotherapy in the treatment of patients with borderline personality disorder: results of a survey among psychiatrists in private practices. *International Clinical Psychopharmacology* 2014;**29**(4):224–8. [DOI: 10.1097/YIC.0000000000000021; PMC4047315; PUBMED: 24896541]

**Kongerslev 2015**

Kongerslev MT, Chanen AM, Simonsen E. Personality disorder in childhood and adolescence comes of age: a review of the current evidence and prospects for future research. *Scandinavian Journal of Child and Adolescent Psychiatry and Psychology* 2015;**3**(1):31–48. [DOI: 10.21307/sjcap-2015-004]

**Lau 1995**

Lau J, Schmid CH, Chalmers TC. Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. *Journal of Clinical Epidemiology* 1995;**48**(1): 45–57. [PUBMED: 7853047]

**Lenzenweger 2007**

Lenzenweger MF, Lane MC, Loranger AW, Kessler RC. DSM-IV personality disorders in the National Comorbidity Survey Replication. *Biological Psychiatry* 2007;**62**(6): 553–64. [DOI: 10.1016/j.biopsych.2006.09.019; PMC2044500; PUBMED: 17217923]

**Levine 1986**

Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. *Psychopharmacology Bulletin* 1986;**22**(2):343–81. [PUBMED: 3774930]

**Lieb 2004**

Lieb K, Zanarini MC, Schmahl C, Linehan MM, Bohus M. Borderline personality disorder. *Lancet* 2004;**364** (9432):453–61. [DOI: 10.1016/S0140-6736(04)16770-6; PUBMED: 15288745]

**Linehan 1997**

Linehan MM. Behavioral treatments of suicidal behaviors: definitional obfuscation and treatment outcomes. *Annals of the New York Academy of Sciences* 1997;**836**:302–28. [PUBMED: 9616806]

**Links 2009**

Links PS, Kolla N. Assessing and managing suicide risk. In: Oldham JM, Skodol AE, Bender DS editor(s). *Essentials of Personality Disorders*. 1st Edition. Arlington (VA): American Psychiatric Publishing, Inc., 2009:343–60. [ISBN 978–1–58562–358–7]

**Lundh 2012**

Lundh A, Sismondo S, Lexchin J, Busuioic OA, Bero L. Industry sponsorship and research outcome. *Cochrane Database of Systematic Reviews* 2012, issue 12:MR000033. [DOI: 10.1002/14651858.MR000033.pub2; PUBMED: 23235689]

**Makela 2006**

Makela EH, Moeller KE, Fullen JE, Gunel E. Medication utilization patterns and methods of suicidality in borderline personality disorder. *Annals of Pharmacotherapy* 2006;**40**(1): 49–52. [DOI: 10.1345/aph.1E479; PUBMED: 16303987]

**Martinho 2014**

Martinho E, Fitzmaurice GM, Frankenburg FR, Zanarini MC. Pro re nata (as needed) psychotropic medication use in patients with borderline personality disorder and subjects with other personality disorders over 14 years of prospective follow-up. *Journal of Clinical Psychopharmacology* 2014;**34**(4):499–503. [DOI: 10.1097/jcp.0000000000000132; PMC4077949; PUBMED: 24875066]

**Meyer-Lindenberg 2011**

Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. *Natural Reviews. Neuroscience* 2011;**12**(9):524–38. [DOI: 10.1038/nrn3044; PUBMED: 21852800]

**Moher 1998**

Moher D, Pham B, Jones A, Cook DJ, Jadad A, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? *Lancet* 1998;**352**(9128):609–13. [DOI: 10.1016/S0140-6736(98)01085-X; PUBMED: 9746022]

**Moher 1999**

Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. *Lancet* 1999;**354**(9193):1896–900. [PUBMED: 10584742]

**Montgomery 1979**

Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. *The British Journal of Psychiatry* 1979;**134**:382–9. [PUBMED: 444788]

**Munk-Jørgensen 2010**

Munk-Jørgensen P, Najjarq Lund M, Bertelsen A. Use of ICD-10 diagnoses in Danish psychiatric hospital-based services in 2001–2007. *World Psychiatry* 2010;**9**(3):183–4. [PMC2948730; PUBMED: 20975866]

**Mustafa 2013**

Mustafa RA, Santesso N, Brozek J, Akl EA, Walter SD, Norman G, et al. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence

syntheses. *Journal of Clinical Epidemiology* 2013;**66**(7):736–42. [DOI: 10.1016/j.jclinepi.2013.02.004; PUBMED: 23623694]

**National Health and Medical Research Council 2013**

National Health and Medical Research Council (Australia). *Clinical Practice Guideline for the Management of Borderline Personality Disorder*. Canberra (ACT): National Health and Medical Research Council, 2013. [www.nhmrc.gov.au/guidelines/publications/mh25]

**Ng 2016**

Ng FY, Bourke ME, Grenyer BF. Recovery from borderline personality disorder: a systematic review of the perspectives of consumers, clinicians, family and carers. *PLoS One* 2016;**11**(8):e0160515. [DOI: 10.1371/journal.pone.0160515; PMC4978398; PUBMED: 27504634]

**NICE 2009**

National Collaborating Centre for Mental Health (Commissioned by the National Institute for Health and Clinical Excellence). *Borderline personality disorder: treatment and management*. NICE clinical guideline 78. [tinyurl.com/y75eqzyx](http://tinyurl.com/y75eqzyx) (accessed 12 March 2010).

**Niesten 2016**

Niesten IJ, Karan E, Frankenburg FR, Fitzmaurice GM, Zanarini MC. Description and prediction of the income status of borderline patients over 10 years of prospective follow-up. *Personality and Mental Health* 2016;**10**(4): 285–92. [DOI: 10.1002/pmh.1331; PUBMED: 26864557]

**Osman 2001**

Osman A, Bagge CL, Gutierrez PM, Konick LC, Kopper BA, Barrios FX. The Suicidal Behaviors Questionnaire-Revised (SBQ-R): validation with clinical and nonclinical samples. *Assessment* 2001;**8**(4):443–54. [DOI: 10.1177/107319110100800409; PUBMED: 11785588]

**Overall 1962**

Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. *Psychological Reports* 1962;**10**(3):799–812. [DOI: 10.2466/pr0.1962.10.3.799]

**Paris 2007**

Paris J, Gunderson J, Weinberg I. The interface between borderline personality disorder and bipolar spectrum disorders. *Comprehensive Psychiatry* 2007;**48**(2):145–54. [DOI: 10.1016/j.comppsy.2006.10.001; PUBMED: 17292705]

**Paris 2015**

Paris J. Why patients with severe personality disorders are overmedicated. *Journal of Clinical Psychiatry* 2015;**76**(4):e521. [DOI: 10.4088/JCP.14com09441; PUBMED: 25919846]

**Paton 2015**

Paton C, Crawford MJ, Bhatti SF, Patel MX, Barnes TE. The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK Mental Health Services. *Journal of Clinical Psychiatry* 2015;**76**(4):e512–8. [DOI: 10.4088/JCP.14m09228; PUBMED: 25919844]



- Perez 2007**  
Perez V, Barrachina J, Soler J, Pascual JC, Campins MJ, Puigdemont D, et al. The clinical global impression scale for borderline personality disorder patients (CGI-BPD): a scale sensible to detect changes [Impresión clínica global para pacientes con trastorno límite de la personalidad (ICG-TLP): una escala sensible al cambio]. *Actas Españolas de Psiquiatría* 2007;**35**(4):229–35. [PUBMED: 17592784]
- Pompili 2017**  
Pompili M, Longo L, Dominici G, Serafini G, Lamis DA, Sarris J, et al. Polyunsaturated fatty acids and suicide risk in mood disorders: a systematic review. *Progress in Neuro-psychopharmacology & Biological Psychiatry* 2017;**6**(74): 43–56. [DOI: 10.1016/j.pnpbp.2016.11.007; PUBMED: 27940200]
- Review Manager 2014 [Computer program]**  
Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
- Rossouw 2012**  
Rossouw TI, Fonagy P. Mentalization-based treatment for self-harm in adolescents: a randomized controlled trial. *Journal of the American Academy of Child and Adolescent Psychiatry* 2012;**51**(12):1304–13. [DOI: 10.1016/j.jaac.2012.09.018; PUBMED: 23200287]
- Sansone 2003**  
Sansone RA, Rytwinski D, Gaither GA. Borderline personality and psychotropic medication prescription in an outpatient psychiatry clinic. *Comprehensive Psychiatry* 2003;**44**(6):454–8. [DOI: 10.1016/S0010-440X(03)00147-0; PUBMED: 14610722]
- Savović 2012a**  
Savović J, Jones H, Altman D, Harris R, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. *Health Technology Assessment* 2012;**16**(35):1–82. [DOI: 10.3310/hta16350; PUBMED: 22989478]
- Savović 2012b**  
Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. *Annals of Internal Medicine* 2012;**157**(6):429–38. [DOI: 10.7326/0003-4819-157-6-201209180-00537; PUBMED: 22945832]
- Schulz 1995**  
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *JAMA* 1995;**273**(5):408–12. [PUBMED: 7823387]
- Silk 2015**  
Silk KR. Management and effectiveness of psychopharmacology in emotionally unstable and borderline personality disorder. *Journal of Clinical Psychiatry* 2015;**76**(4):e524–5. [DOI: 10.4088/JCP.14com09534; PUBMED: 25919848]
- Skodol 2002**  
Skodol AE, Gunderson JG, McGlashan TH, Dyck IR, Stout RL, Bender DS, et al. Functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder. *American Journal of Psychiatry* 2002;**159**(2):276–83. [DOI: 10.1176/appi.ajp.159.2.276; PUBMED: 11823271]
- Soetmann 2008a**  
Soeteman DI, Hakkaart-van Roijen L, Verheul R, Busschbach JJ. The economic burden of personality disorders in mental health care. *Journal of Clinical Psychiatry* 2008;**69**(2):259–65. [PUBMED: 18363454]
- Soetmann 2008b**  
Soeteman DI, Verheul R, Busschbach JJ. The burden of disease in personality disorders: diagnosis-specific quality of life. *Journal of Personality Disorders* 2008;**22**(3):259–68. [DOI: 10.1521/pedi.2008.22.3.259; PUBMED: 18540798]
- Soloff 2002**  
Soloff PH, Lynch KG, Kelly TM. Childhood abuse as a risk factor for suicidal behavior in borderline personality disorder. *Journal of Personality Disorders* 2002;**16**(3): 201–14. [PUBMED: 12136678]
- Spielberger 1988**  
Spielberger CD. *Manual for the State-Trait Anger Expression Inventory*. Odessa (FL): Psychological Assessment Resources, 1988.
- Stapp 2012**  
Stapp SD. Development of borderline personality disorder in adolescence and young adulthood: introduction to the special section. *Journal of Abnormal Child Psychology* 2012;**40**(1):1–5. [DOI: 10.1007/s10802-011-9594-3; PMC3865353; PUBMED: 22116635]
- Stern 1938**  
Stern A. Psychoanalytic investigation of and therapy in the borderline group of neuroses. *Psychoanalytic Quarterly* 1938;**7**:467–89.
- Sterne 2013**  
Sterne JA. Why the Cochrane risk of bias tool should not include funding source as a standard item. *Cochrane Database of Systematic Reviews* 2013; Vol. 12:ED000076. [DOI: 10.1002/14651858.ED000076; PUBMED: 24575440]
- Sterne 2017**  
Sterne JAC, Egger M, Moger D, Boutron I, editor(s). Chapter 10: Addressing reporting biases. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor (s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).
- Stiglmayr 2005**  
Stiglmayr CE, Grathwol T, Linehan MM, Ihorst G, Fahrenberg J, Bohus M. Aversive tension in patients with borderline personality disorder: a computer-based

- controlled field study. *Acta Psychiatrica Scandinavica* 2005; **111**(5):372–9. [DOI: 10.1111/j.1600-0447.2004.00466.x; PUBMED: 15819731]
- Stone 1993**  
Stone MH. Long-term outcome in personality disorders. *British Journal of Psychiatry* 1993; **162**:299–313. [PUBMED: 8453424]
- Storebø 2014**  
Storebø OJ, Simonsen E. Is ADHD an early stage in the development of borderline personality disorder?. *Nordic Journal of Psychiatry* 2014; **68**(5):289–95. [DOI: 10.3109/08039488.2013.841992; PUBMED: 24117059]
- Ten Have 2016**  
Ten Have M, Verheul R, Kaasenbrood A, Van Dorsselaer S, Tuithof M, Kleinjan M, et al. Prevalence rates of borderline personality disorder symptoms: a study based on the Netherlands Mental Health Survey and Incidence Study-2. *BMC Psychiatry* 2016; **16**:249. [DOI: 10.1186/s12888-016-0939-x; PMC4949762; PUBMED: 27435813]
- Thorlund 2009**  
Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analysis?. *International Journal of Epidemiology* 2009; **38**(1):276–86. [DOI: 10.1093/ije/dyn179; PUBMED: 18824467]
- Tomko 2014**  
Tomko RL, Trull TJ, Wood PK, Sher KJ. Characteristics of borderline personality disorder in a community sample: comorbidity, treatment utilization, and general functioning. *Journal of Personality Disorders* 2014; **28**(5):734–50. [DOI: 10.1521/pedi\_2012\_26\_093; PMC3864176 ; PUBMED: 25248122]
- Torgersen 2001**  
Torgersen S, Kringlen E, Cramer V. The prevalence of personality disorders in a community sample. *Archives of General Psychiatry* 2001; **58**(6):590–6. [PUBMED: 11386989]
- Torgersen 2012**  
Torgersen S. Epidemiology. In: Widiger TA editor(s). *The Oxford Handbook of Personality Disorders*. New York (NY): Oxford University Press, 2012:186–205. [DOI: 10.1093/oxfordhb/9780199735013.013.0009; ISBN 978-0-19-973501-3]
- Trull 2010**  
Trull TJ, Jahng S, Tomko RL, Wood PK, Sher KJ. Revised NESARC personality disorder diagnoses: gender, prevalence, and comorbidity with substance dependence disorders. *Journal of personality disorders* 2010; **24**(4):412–26. [DOI: 10.1521/pedi.2010.24.4.412; PMC3771514; PUBMED: 20695803]
- Tyrer 2005**  
Tyrer P, Nur U, Crawford M, Karlsen S, McLean C, Rao B, et al. The Social Functioning Questionnaire: a rapid and robust measure of perceived functioning. *International Journal of Social Psychiatry* 2005; **51**(3):265–75. [PUBMED: 16252794]
- Tyrer 2015**  
Tyrer P, Reed GM, Crawford MJ. Classification, assessment, prevalence, and effect of personality disorders. *Lancet* 2015; **385**(9969):717–26. [DOI: 10.1016/S0140-6736(14)61995-4]
- van Asselt 2007**  
van Asselt ADI, Dirksen CD, Arntz A, Severens JL. The cost of borderline personality disorder: societal cost of illness in BPD-patients. *European Psychiatry* 2007; **22**(6):354–61. [DOI: doi:10.1016/j.eurpsy.2007.04.001; PUBMED: 17544636]
- Westra 2002**  
Westra HA, Steward SH, Conrad BE. Naturalistic manner of benzodiazepine use and cognitive behavioral therapy outcome in panic disorder with agoraphobia. *Journal of Anxiety Disorders* 2002; **16**(3):233–46. [PUBMED: 12214810]
- Wetterslev 2008**  
Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. *Journal of Clinical Epidemiology* 2008; **61**(1):64–75. [DOI: 10.1016/j.jclinepi.2007.03.013; PUBMED: 18083463]
- Wetterslev 2009**  
Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. *BMC Medical Research Methodology* 2009; **9**:86. [DOI: 10.1186/1471-2288-9-86; PMC2809074; PUBMED: 20042080]
- WHO 1993**  
World Health Organisation. *The ICD-10 Classification of Mental and Behavioral Disorders: Diagnostic Criteria for Research*. Geneva (CH): World Health Organization, 1993.
- Wood 2008**  
Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. *BMJ* 2008; **336**(7644):601–5. [DOI: doi.org/10.1136/bmj.39465.451748.AD; 18316340; PMC2267990]
- Yen 2004**  
Yen S, Shea MT, Sanislow CA, Grilo CM, Skodol AE, Gunderson JG, et al. Borderline personality disorder criteria associated with prospectively observed suicidal behavior. *American Journal of Psychiatry* 2004; **161**(7):1296–8. [DOI: 10.1176/appi.ajp.161.7.1296; PUBMED: 15229066]
- Zanarini 1998**  
Zanarini MC, Frankenburg FR, DeLuca CJ, Hennen J, Khera GS, Gunderson JG. The pain of being borderline: dysphoric states specific to borderline personality disorder. *Harvard Review of Psychiatry* 1998; **6**(4):201–7. [DOI: 10.3109/10673229809000330; PUBMED: 10370445]

### Zanarini 2003

Zanarini MC, Vujanovic AA, Parachini EA, Boulanger JL, Frankenburg FR, Hennen J. Zanarini Rating Scale for Borderline Personality Disorder (Zan-BPD): a continuous measure of DSM-IV borderline psychopathology. *Journal of Personality Disorders* 2003;**17**(3):233–42. [PUBMED: 12839102]

### Zanarini 2004a

Zanarini MC, Frankenburg FR, Hennen J, Silk KR. Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years. *Journal of Clinical Psychiatry* 2004;**65**(1):28–36. [PUBMED: 14744165]

### Zanarini 2004b

Zanarini MC, Frankenburg FR, Hennen J, Reich DB, Silk KR. Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission. *American Journal of Psychiatry* 2004;**161**(11):2108–14. [DOI: 10.1176/appi.ajp.161.11.2108; PUBMED: 15514413]

### Zanarini 2005

Zanarini MC, Frankenburg FR, Hennen J, Reich DB, Silk KR. The McLean Study of Adult Development (MSAD): overview and implications of the first six years of prospective follow-up. *Journal of Personality Disorders* 2005;**19**(5): 505–23. [DOI: 10.1521/pedi.2005.19.5.505; PUBMED: 16274279]

### Zanarini 2007

Zanarini MC, Frankenburg FR, Reich DB, Silk KR, Hudson JI, McSweeney LB. The subsyndromal phenomenology of borderline personality disorder: a 10-year follow-up study. *American Journal of Psychiatry* 2007;**164**(6):929–35. [DOI: 10.1176/ajp.2007.164.6.929; PUBMED: 17541053]

### Zanarini 2010

Zanarini MC, Frankenburg FR, Reich DB, Fitzmaurice G. The 10-year course of psychosocial functioning among patients with borderline personality disorder and axis II comparison subjects. *Acta Psychiatrica Scandinavica* 2010;**122**(2):103–9. [DOI: doi:10.1111/j.1600-0447.2010.01543.x; PMC3876887; PUBMED: 20199493]

### Zanarini 2012

Zanarini MC, Frankenburg FR, Reich B, Fitzmaurice G. Attainment and stability of sustained symptomatic remission and recovery among patients with borderline personality disorder and axis II comparison subjects: a 16-year prospective follow-up study. *American Journal of Psychiatry* 2012;**169**(5):476–83. [DOI: 10.1176/appi.ajp.2011.11101550; PMC3509999; PUBMED: 22737693]

### Zanarini 2015

Zanarini MC, Frankenburg FR, Reich DB, Harned AL, Fitzmaurice GM. Rates of psychotropic medication use reported by borderline patients and axis II comparison subjects over 16 years of prospective follow-up. *Journal of Clinical Psychopharmacology* 2015;**35**(1):63–7. [DOI: 10.1097/JCP.0000000000000232; PMC4276426; PUBMED: 25384261]

## References to other published versions of this review

### Stoffers 2010

Stoffers JM, Völm BA, Rucker G, Timmer A, Huband N, Lieb K. Pharmacological interventions for borderline personality disorder. *Cochrane Database of Systematic Reviews* 2010, Issue 6. [DOI: 10.1002/14651858.CD005653.pub2; PMC4169794 ; PUBMED: 20556762]

\* Indicates the major publication for the study

## APPENDICES

### Appendix I. DSM diagnostic criteria for BPD (301.83)

DSM Third Edition (DSM-III; APA 1980) 301.83 BPD	DSM Fourth Edition Text Revision (DSM-IV-TR; APA 2000) 301.83 BPD	DSM Fifth Edition (DSM-5; APA 2013) 301.83 BPD
<b>Diagnostic criterion A</b> 5 of the following are required 1. Impulsivity or unpredictability in at least 2 areas that are potentially self-damaging (e.	<b>Diagnostic criterion A</b> A pervasive pattern of instability of interpersonal relationships, self-image, and affects, and marked impulsivity beginning by	<b>Diagnostic criterion A</b> A pervasive pattern of instability of interpersonal relationships, self-image, and affects, and marked impulsivity, beginning

(Continued)

<p>g. spending, sex, substance use, shoplifting, overeating, physically self-damaging acts)</p> <p>2. A pattern of unstable and intense interpersonal relationships (e.g. marked shifts of attitude, idealization, devaluation, manipulation (consistently using others for one's own ends))</p> <p>3. Inappropriate, intense anger or lack of control of anger (e.g. frequent displays of temper, constant anger)</p> <p>4. Identity disturbance manifested by uncertainty about several issues relating to identity, such as self-image, gender identity, long-term goals or career choice, friendship patterns, values, and loyalties (e.g. 'Who am I', 'I feel like I am my sister when I am good')</p> <p>5. Affective instability: marked shifts from normal mood to depression, irritability, or anxiety, usually lasting a few hours and only rarely more than a few days, with a return to normal mood</p> <p>6. Intolerance of being alone (e.g. frantic efforts to avoid being alone, depressed when alone)</p> <p>7. Physically self-damaging acts (e.g. suicidal gestures, self-mutilation, recurrent accidents or physical fights)</p> <p>8. Chronic feelings of emptiness or boredom</p>	<p>early adulthood and present in a variety of contexts, as indicated by 5 (or more) of the following</p> <p>1. Frantic efforts to avoid real or imagined abandonment (note: do not include suicidal or self-mutilating behavior covered in criterion 5)</p> <p>2. A pattern of unstable and intense interpersonal relationships characterized by alternating between extremes of idealization and devaluation</p> <p>3. Identity disturbance: markedly and persistently unstable self-image or sense of self</p> <p>4. Impulsivity in at least 2 areas that are potentially self-damaging (e.g. spending, sex, substance abuse, reckless driving, binge eating) (note: do not include suicidal or self-mutilating behavior covered in criterion 5)</p> <p>5. Recurrent suicidal behavior, gestures, or threats, or self-mutilating behavior</p> <p>6. Affective instability due to a marked reactivity of mood (e.g. intense episodic dysphoria, instability, or anxiety usually lasting a few hours and only rarely more than a few days)</p> <p>7. Chronic feelings of emptiness</p> <p>8. Inappropriate, intense anger or difficulty controlling anger (e.g. frequent displays of temper, constant anger, recurrent physical fights)</p> <p>9. Transient, stress-related paranoid ideation or severe dissociative symptoms</p>	<p>by early adulthood and present in a variety of contexts, as indicated by 5 (or more) of the following</p> <p>1. Frantic efforts to avoid real or imagined abandonment (note: do not include suicidal or self-mutilating behavior covered in criterion 5)</p> <p>2. A pattern of unstable and intense interpersonal relationships characterized by alternating between extremes of idealization and devaluation</p> <p>3. Identity disturbance: markedly and persistently unstable self-image or sense of self</p> <p>4. Impulsivity in at least 2 areas that are potentially self-damaging (e.g. spending, sex, substance abuse, reckless driving, binge eating) (note: do not include suicidal or self-mutilating behavior covered in criterion 5)</p> <p>5. Recurrent suicidal behavior, gestures or threats, or self-mutilating behavior</p> <p>6. Affective instability due to a marked reactivity of mood (e.g. intense episodic dysphoria, irritability, or anxiety of mood) usually lasting a few hours and only rarely more than a few days</p> <p>7. Chronic feelings of emptiness</p> <p>8. Inappropriate, intense anger or difficulty controlling anger (e.g. frequent displays of temper, constant anger, recurrent physical fights)</p> <p>9. Transient, stress-related paranoid ideation or severe dissociative symptoms</p>
---	--	---

<p><b>Diagnostic criterion B</b> If under 18, does not meet the criteria for Identity Disorder</p>		
--	--	--

BPD: Borderline personality disorder; DSM: Diagnostic and Statistical Manual of Mental Disorders

## Appendix 2. ICD-10 research criteria for emotionally unstable personality disorder (F60.3)

<b>F 60.30: ICD-10 Emotionally unstable personality disorder, impulsive type</b>	<b>F 60.31: Emotionally unstable personality disorder, border-line type</b>
<p><b>Diagnostic criterion A</b> The general criteria of personality disorder (F60) must be met</p>	<p><b>Diagnostic criterion A</b> The general criteria of personality disorder (F60) must be met</p>
<p><b>Diagnostic criterion B</b> At least 3 of the following must be present, 1 of which is 2</p> <ol style="list-style-type: none"> <li>1. Marked tendency to act unexpectedly and without consideration of the consequences</li> <li>2. Marked tendency to quarrelsome behaviour and to conflicts with others, especially when impulsive acts are thwarted or criticized</li> <li>3. Liability of outbursts of anger or violence, with inability to control the resulting behavioural explosions</li> <li>4. Difficulty in maintaining any course of action that offers no immediate reward</li> <li>5. Unstable and capricious mood</li> </ol>	<p><b>Diagnostic criterion B</b> At least 3 of the symptoms mentioned in criterion B (F60.30) must be present, and in addition at least 2 of the following</p> <ol style="list-style-type: none"> <li>6. Disturbances in and uncertainty about self-image, aims and internal preferences (including sexual)</li> <li>7. Liability to become involved in intense and unstable relationships, often leading to emotional crises</li> <li>8. Excessive efforts to avoid abandonment</li> <li>9. Recurrent threats or acts of self-harm</li> <li>10. Chronic feelings of emptiness</li> </ol>
<p>ICD-10: International Classification of Diseases - Tenth Edition</p>	

## Appendix 3. Medline search strategy

- 1 Borderline Personality Disorder/
- 2 ((borderline or border-line) adj3 (state\* or personalit\*)).kf,tw.
- 3 (“Axis II” or “Cluster B” or flamboyant or “F60.3” or “F60.30” or “F60.31”).kf,tw.
- 4 (idealization adj5 devaluation).kf,tw.
- 5 ((vulnerable or hyperbolic) adj3 temperament).kf,tw.
- 6 (((unstab\* or instab\* or poor or disturb\* or fail\* or weak or dysregulat\*) adj3 (self\* or impuls\* or interperson\* or identit\* or relationship\* or emotion\* or affect\*)) and (personality or character or PD)).kf,tw.
- 7 (impulsiv\* adj5 (behavio:r or character or personalit\*)).kf,tw.
- 8 (self adj3 (injur\* or damag\* or destruct\* or harm\* or hurt\* or mutilat\*)).kf,tw.
- 9 (suicidal adj3 behavio:r).kf,tw.
- 10 (feel\* adj3 (empt\* or bored\*)).kf,tw.
- 11 (anger adj5 control\*).kf,tw.
- 12 (risk-taking adj3 behavio:r).kf,tw.
- 13 or/1-12
- 14 randomized controlled trial.pt.
- 15 controlled clinical trial.pt.
- 16 randomi#ed.ab.
- 17 placebo.ab.
- 18 randomly.ab.
- 19 trial.ab.
- 20 groups.ab.
- 21 drug therapy.fs.
- 22 or/14-21
- 23 exp Animals/ not Humans/
- 24 22 not 23

## Appendix 4. 'Risk of bias' domains and criteria for assigning judgements

### Selection bias

#### Random sequence generation

1. **Low risk of bias.** The method used was adequate (e.g. computer-generated random numbers, table of random numbers) or was unlikely to introduce selection bias.
2. **Unclear risk of bias.** Information was insufficient for assessment of whether the method used could introduce selection bias.
3. **High risk of bias.** The method used was likely to introduce bias.

#### Allocation concealment

1. **Low risk of bias.** The method used (e.g. central allocation) was unlikely to bias allocation to groups.
2. **Unclear risk of bias.** Information was insufficient for assessment of whether the method used could bias allocation to groups.
3. **High risk of bias.** The method used (e.g. open random allocation schedule) could bias allocation to groups.

#### Performance bias (blinding of participants and personnel)

1. **Low risk of bias.** The method of blinding was described sufficiently and blinding was conducted in a satisfactory way.
2. **Unclear risk of bias.** Information was insufficient for assessment of whether adequate blinding was used and whether it was likely to introduce bias on the estimate of effect.
3. **High risk of bias.** No blinding or incomplete blinding.

#### Detection bias (blinding of outcome assessment)

1. **Low risk of bias.** The method of blinding was described and blinding was conducted in a satisfactory way.
2. **Unclear risk of bias.** Information was insufficient for assessment of whether the type of blinding used was likely to bias the estimate of effect.
3. **High risk of bias.** No blinding or incomplete blinding.

#### Attrition bias (incomplete outcome data)

1. **Low risk of bias.** Underlying reasons for missing data probably would not affect outcome measurement regarding effects of methylphenidate, as all missing data can be considered as missing at random or all data were reported.
2. **Unclear risk of bias.** Information was insufficient for assessment of whether missing data or the method used to handle missing data was likely to bias the estimate of effect.
3. **High risk of bias.** The crude estimate of effects could be biased given the reasons for the missing data, or the methods used to handle missing data are unsatisfactory.

#### Reporting bias (selective reporting)

1. **Low risk of bias.** The trial protocol was available and all prespecified outcomes of interest were reported.
2. **Unclear risk of bias.** Information was insufficient for assessment of whether selective outcome reporting could have occurred.
3. **High risk of bias.** Not all of the primary outcomes specified beforehand were reported or participants were excluded after randomisation.

## Other potential sources of bias

### Vested interest

1. **Low risk of bias.** The trial was not funded by any parties that might be considered to have a conflict of interest (e.g. a manufacturer of methylphenidate).
2. **Unclear risk of bias.** The source of funding was not clear.
3. **High risk of bias.** The trial was funded by parties that might have had a conflict of interest (e.g. a manufacturer of methylphenidate) or potential conflicts of interest were reported by trial authors.

### Other sources of bias

1. **Low risk of bias.** The trial appeared to be free of other sources of bias.
2. **Unclear risk of bias.** Information was inadequate for assessment of other possible sources of bias.
3. **High risk of bias.** Other sources of bias were identified.

Seven of the above domains are specified in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2017). We added an eighth domain - vested interest. Andreas Lundh and colleagues illustrate the many subtle mechanisms through which sponsorship and conflict of interest may influence intervention effects on outcomes. For more information, please see editorials by Bero 2013 and Sterne 2013, and the commentary by Gøtzsche 2015.

## CONTRIBUTIONS OF AUTHORS

All of the authors contributed to writing this protocol. Jutta Stoffers-Winterling is the guarantor for the review.

## DECLARATIONS OF INTEREST

Jutta M Stoffers-Winterling (JSW) is a board-certified psychologist ('Psychologische Psychotherapeutin', cognitive behaviour therapy), who has worked on a Dialectical Behaviour Therapy (DBT) ward, attended courses on DBT and Schema-Focused Therapy. JSW has been involved in the preparation of the World Federation of Societies of Biological Psychiatry Guidelines for the Treatment of Personality Disorders (Herpertz 2007).

Ole Jakob Storebø is an Editor with CDPLP.

Jessica T Mattivi's institution received a grant from the Federal Ministry for Education and Research (BMBF) for a systematic review on psychosocial interventions for self-harm in adolescents.

Birgit A Völlm - none known.

Signe Nielsen - none known.

Maja Lærke Kielsholm - none known.

Erlend G Faltinsen - none known.

Erik Simonsen - none known.

Klaus Lieb (KL) is an Editor with CDPLP. He is a board-certified cognitive behaviour therapist with a special interest in schema therapy. KL has been involved in the preparation of the World Federation of Societies of Biological Psychiatry Guidelines for the Treatment of Personality Disorders (Herpertz 2007).

## SOURCES OF SUPPORT

### Internal sources

- Psychiatric Research Unit, Region Zealand Psychiatry, Roskilde, Denmark.
- Ole Jakob Storebø, Maja Lærke Kielsholm, Signe Sofie Nielsen, and Erik Simonsen worked on this protocol during office hours.

### External sources

- None, Other.

## NOTES

This is a new protocol for a new review, which will replace the current published review: Stoffers J, Völlm BA, Rucker G, Timmer A, Huband N, Lieb K. Pharmacological interventions for borderline personality disorder. Cochrane Database of Systematic Reviews 2010, Issue 6. Art. No.: CD005653. DOI: 10.1002/14651858.CD005653.pub2.